European Society of Cardiology Congress 2017
Unmet clinical needs in women at very high risk of cardiovascular events
Results from the Dyslipidemia International Study (DYSIS) have highlighted issues specific to very high risk women. Of the very high risk cohort on statin therapy (n=46,310), 40% were women. These female patients were more likely to be on less potent or lower doses of statins…
read more »
Eligibility for PCSK9 inhibitors in very high risk patients
PCSK9 monoclonal antibody therapy is undoubtedly effective in lowering LDL cholesterol levels in very high risk patients. However, for healthcare systems with finite budgets, cost may be a limiting factor for their use. Consequently, the proportion of these very high risk patients that are eligible…
read more »
Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients
Lipoprotein apheresis is an option in very high risk patients with uncontrolled LDL cholesterol levels despite maximally tolerated lipid lowering therapy. Typically, patients include those with severe familial hypercholesterolaemia (FH, inherited high cholesterol). Yet, while lipoprotein apheresis is effective in reducing LDL cholesterol there are…
read more »
ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses
ESC 2017: Further data from the ORION-1 trial, first reported earlier this year, showed a sustained and durable LDL cholesterol lowering response extending to Day 360 after one or two doses (1,2). Inclisiran is a novel siRNA inhibitor to PCSK9 which specifically targets intracellular PCSK9…
read more »
TAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia
ESC Congress 2017: First data in children with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) aged from 12 years show that evolocumab is an effective option, added to statin and ezetimibe with or without lipoprotein apheresis (1). Homozygous FH is a rare genetic disorder characterised…
read more »
ESC Congress 2017: CANTOS shows it’s not all about lipids
The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study (1) showed that treatment with canakinumab, an inhibitor of interleukin-1β (IL-1β), reduced the risk of major adverse cardiovascular events. Lead author, Professor Paul Ridker (Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, USA) compared…
read more »
FOURIER update: new impetus for guideline groups to reconsider LDL targets
ESC Congress 2017: Not lower is better but lowest is best, according to findings from a new analysis from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial with the PCSK9 inhibitor evolocumab (1). According to lead author…
read more »
